Our results demonstrate that tumor endothelial cells contribute to immunosuppressive feed-back loops in response to agonistic CD40 mAb therapy, which restrict the response to immunotherapy through IFNγ-driven expression of IDO1 that inhibits T-cell activation. The gene discussed is IFNG; the disease is neoplasm.